89Sr治疗乳腺癌和前列腺癌多发性骨转移的临床观察

目的 探讨放射性核素89Sr治疗乳腺癌和前列腺癌多发性骨转移患者的临床效果.方法 回顾性分析30例乳腺癌和40例前列腺癌多发性骨转移患者接受89Sr治疗的病例资料,采用Karnofsky评分量表和骨显像方法进行疗效评估.结果 乳腺癌组的止痛总有效率为79%,前列腺癌组的止痛总有效率为85%,两组患者之间差异无统计学意义(x2=0.78,P＞0.05).两组患者的生存质量均有明显改善,治疗前后两组患者的Karnofsky评分均有明显提高(t=2.46,P＜0.05;t=2.68,P＜0.05).治疗后两组患者均未见明显骨髓抑制与肝肾功能损伤.结论 89Sr治疗乳腺癌和前列腺癌多发性骨转移止痛效果良好,患者生存质量有明显提高.

Clinical observation of 89Sr treatment efficacy of multiple bone metastases in breast and prostate cancer patients

Objective To evaluate the efficacy of 89Sr in treatment of multiple bone metastases of breast and prostate cancer patients. Methods Seventy multiple bone metastases patients (30 females with breast cancer and 40 males with prostate cancer) were treated with 89Sr. The clinical effectiveness was assessed by Karnofsky performance score and whole body bone scanning data. Results The total pain relief rate was 79% in bone metastases of breast cancer and 85% in bone metastases of prostate cancer, respectively. There was no significant differences between the two groups (x2 = 0.78, P＞0.05 ). The Karnofsky score was significantly improved in both groups (t = 2.46, P＜0.05; t = 2.68, P＜0.05). The bone marrow depression and the damage of liver and kidney were not observed in the two groups. Conclusion The analgesic effect of 89Sr treatment was good, and the quality of life was improved in patients with multiple bone metastases breast or prostate cancer.